Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on June 16, 2022. The company is an emerging growth company incorporated in Nevada with principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement that the Company has been invited to present data on reversing resistance to HER2 targeted immunotherapy at the HER2 Targeted Therapy Summit in Boston.
Outlook, Risks, and Management Commentary
Management commentary is limited to the press release attached as Exhibit 99.1, which details the upcoming data presentation. The filing does not contain specific guidance, risk factors, contingencies, or unusual items beyond the standard disclosure of the event.
Investor Verification Checklist
- Verify the date and location of the HER2 Targeted Therapy Summit in Boston.
- Review the attached press release (Exhibit 99.1) for specific details on the data to be presented regarding HER2 targeted immunotherapy resistance.
- Confirm the company's status as an emerging growth company and its implications for financial reporting.